aging

Health By Elizabeth Cooney

The ‘active grandparent hypothesis’: New research explores how we’ve evolved to move more and live longer

Biotech By Megan Molteni

Anti-aging research foundation stands by ouster of Aubrey de Grey after investigation concludes

A STAT Investigation By Megan Molteni and Mario Aguilar

Inside the downfall of longevity crusader Aubrey de Grey — and the cult of personality that concealed a pattern of harassment

Biotech By Megan Molteni

Scientist Aubrey de Grey made inappropriate sexual comments to two female entrepreneurs, independent investigation finds

First Opinion Podcast By Patrick Skerrett

Listen: An ENT physician & an advocate on the high monetary and social costs of hearing loss

Health By Alicia Diaz

The decision to pull loved ones out of nursing homes when the pandemic hit was a great alternative — for those who could afford it 

First Opinion By Laura Fraade-Blanar, Ryan Best and Vijeth Iyengar

Ridesharing can help older people be functionally independent in their homes, communities

Health By Jonathan Saltzman — Boston Globe

Retired neurologist with Alzheimer’s knows firsthand the risks of Aduhelm

First Opinion By Jason Resendez and Stephanie Monroe

Clinical research doesn’t reflect the Alzheimer’s population. That needs to change

First Opinion By Andrew C. von Eschenbach

With Aduhelm, history can repeat itself by following cancer’s success

First Opinion By Madhav Thambisetty

‘When Memory Fades’: Misinformation about Alzheimer’s disease and Aduhelm must be limited

STAT Summit By Elizabeth Cooney

‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

Biotech By Adam Feuerstein

FDA, under fire from critics, revises prescribing information for Biogen’s Alzheimer’s drug

First Opinion By Emil D. Kakkis

Aduhelm’s accelerated approval offers a promising roadmap for rare neurological diseases

First Opinion By Josh Marx

Outdated Medicare rules threaten older Americans’ access to home medical equipment

Pharmalot By Ed Silverman

Revised analysis nudges up cost-effective price for Biogen’s Alzheimer’s drug to $3,000 to $8,400 a year

Health By Nicholas St. Fleur

STAT+ Conversations: Can tech change in-home care for seniors?

First Opinion By Madhav Thambisetty

Why a controversial decision won’t stop me from serving on FDA advisory committees

First Opinion By Sam Gandy

6 ways the FDA’s approval of Aduhelm does more harm than good

First Opinion By Ken Marek

The approval of aducanumab isn’t the end of the story. It’s just the beginning

Health By Elizabeth Cooney

‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients

First Opinion By Dana P. Goldman and Darius Lakdawalla

FDA’s approval of aducanumab paves the way for ‘more momentous’ Alzheimer’s breakthroughs

First Opinion By Jim Taylor

Medicare: Cover amyloid PET scans and stop keeping people with dementia in the dark

First Opinion By Nora Super and Diane Ty

Routine cognitive screening can help detect early signs of dementia

In the Lab By Megan Molteni

Reawakened immune cells show promise in mice against zombie cells tied to diseases of aging